STBT5:Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
No edit summary |
||
| (24 intermediate revisions by 2 users not shown) | |||
| Line 160: | Line 160: | ||
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]] | |[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]] | ||
|Disease | |Disease | ||
|Kauser Begum Ravishankar (trainee), with Katie | |||
|2/25/2026 | |||
|5/25/2026 | |||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 182: | Line 182: | ||
|[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]] | |[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]] | ||
|Disease | |Disease | ||
|Karla Sofía Peláez Valdés (trainee); | |||
Katie Schieffer (mentor) | |||
|3/1/2026 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 453: | Line 454: | ||
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] | |[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] | ||
|Disease | |Disease | ||
| | |Katie Schieffer | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |Minimal genetic content added | ||
|- | |- | ||
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | |[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | ||
| Line 497: | Line 498: | ||
|[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]] | |[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]] | ||
|Disease | |Disease | ||
|He Fang | |||
|2/19/2026 | |||
|5/20/2026 | |||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 521: | Line 522: | ||
|9/24/2025 | |9/24/2025 | ||
|12/24/2025 | |12/24/2025 | ||
| | |COMPLETE | ||
| | |12/18/2025 | ||
| | |Katie Schieffer | ||
| | |12/18/2025 | ||
| | | | ||
|- | |- | ||
|[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]] | |[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]] | ||
|Disease | |Disease | ||
| | |Katherine Geiersbach | ||
| | |8/11/2023 | ||
| | |11/11/2203 | ||
| | |COMPLETE | ||
| | |1/8/2025 | ||
| | |Katherine Geiersbach | ||
| | |1/8/2025 | ||
| | | | ||
|- | |- | ||
| Line 562: | Line 563: | ||
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] | |[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] | ||
|Disease | |Disease | ||
| | |Mokhtar Abdelhammed, MD (trainee); | ||
| | Katie Schieffer (mentor) | ||
| | |3/1/2026 | ||
| | |6/30/2026 | ||
| | |COMPLETE | ||
| | |3/3/2026 | ||
| | |Katie Schieffer | ||
|3/4/2026 | |||
| | | | ||
|- | |- | ||
| Line 911: | Line 913: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] | |[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| Line 1,016: | Line 1,018: | ||
|[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]] | |[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]] | ||
|Disease | |Disease | ||
|Shanmugapriya Veeralakumar (trainee); Katie as mentor | |||
|2/23/2026 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 1,096: | Line 1,098: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|- | |- | ||
| Line 1,116: | Line 1,118: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | |[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,193: | Line 1,195: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] | |[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] | ||
| Line 1,269: | Line 1,271: | ||
|9/11/2025 | |9/11/2025 | ||
|12/11/2025 | |12/11/2025 | ||
| | |COMPLETE | ||
| | |12/29/2026 | ||
|Katie Schieffer | |Katie Schieffer | ||
| | |1/7/2026 | ||
| | | | ||
|- | |- | ||
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] | |[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] | ||
|Disease | |Disease | ||
| | |Mokhtar Abdelhammed, MD (trainee); | ||
| | Katie Schieffer (mentor) | ||
| | |3/1/2026 | ||
| | |6/30/2026 | ||
|PENDING | |||
| | | | ||
| | | | ||
| Line 1,302: | Line 1,305: | ||
|2/20/2022 | |2/20/2022 | ||
|12/9/2025 | |12/9/2025 | ||
| | |COMPLETE | ||
| | |2/26/2026 | ||
|Katie Schieffer | |Katie Schieffer | ||
| | |2/26/2026 | ||
| | | | ||
|- | |- | ||
| Line 1,335: | Line 1,338: | ||
|10/13/2025 | |10/13/2025 | ||
|12/31/2025 | |12/31/2025 | ||
| | |COMPLETE | ||
| | |12/24/2025 | ||
|Katie Schieffer | |Katie Schieffer | ||
| | |12/24/2025 | ||
| | | | ||
|- | |- | ||
| Line 1,374: | Line 1,377: | ||
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | |[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | ||
|Disease | |Disease | ||
| | |Maxine Sutcliffe, PhD | ||
| | |1/12/2026 | ||
| | |4/12/2026 | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,483: | Line 1,486: | ||
|[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]] | |[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]] | ||
|Disease | |Disease | ||
|He Fang | |||
|2/19/2026 | |||
|8/20/2026 | |||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 1,527: | Line 1,530: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | |[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | ||
| Line 1,546: | Line 1,549: | ||
|[[STBT5:Periosteal_chondroma|Periosteal chondroma]] | |[[STBT5:Periosteal_chondroma|Periosteal chondroma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,557: | Line 1,560: | ||
|[[STBT5:Enchondroma|Enchondroma]] | |[[STBT5:Enchondroma|Enchondroma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,568: | Line 1,571: | ||
|[[STBT5:Osteochondroma|Osteochondroma]] | |[[STBT5:Osteochondroma|Osteochondroma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,775: | Line 1,778: | ||
|Fang Fang (trainee); Katie Schieffer (mentor) | |Fang Fang (trainee); Katie Schieffer (mentor) | ||
|11/19/2025 | |11/19/2025 | ||
| | |4/15/2026 | ||
|PENDING | |PENDING | ||
| | | | ||
| Line 1,861: | Line 1,864: | ||
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] | |[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] | ||
|Disease | |Disease | ||
|[[STBT5:Epithelioid haemangioma|See STBT5: Epithelioid haemangioma page]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
|[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]] | |||
|- | |||
|[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]] | |||
|Disease | |Disease | ||
| | |[[STBT5:Epithelioid haemangioendothelioma|See STBT5: Epithelioid haemangioendothelioma page]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
| Line 1,891: | Line 1,894: | ||
|- | |- | ||
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]] | |[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]] | ||
|Disease | |||
|[[STBT5:Angiosarcoma|See STBT5: Angiosarcoma page]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | |||
|- | |||
|[[STBT5:Aneurysmal_bone_cyst|Aneurysmal bone cyst]] | |||
|Disease | |Disease | ||
| | | | ||
| Line 1,900: | Line 1,914: | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]] | |[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]] | ||
| Line 2,055: | Line 2,058: | ||
|[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]] | |[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 2,075: | Line 2,067: | ||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]] | ||
|Disease | |Disease | ||
|[[STBT5:Leiomyosarcoma|See STBT5: Leiomyosarcoma page]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
| | |- | ||
| | |[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]] | ||
| | |Disease | ||
| | |Maxine Sutcliffe | ||
| | |2/23/2026 | ||
| | |4/12/2026 | ||
|COMPLETE | |||
|4/27/2026 | |||
|Katie Schieffer | |||
|4/28/2026 | |||
| | | | ||
|- | |- | ||
| Line 2,099: | Line 2,102: | ||
|[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]] | |[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | |[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | ||
| Line 2,130: | Line 2,133: | ||
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]] | |[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
| | |- | ||
| | |[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]] | ||
| | |Disease | ||
| | |[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
|Disease | |Disease | ||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
| | | | ||
====CHAPTER 5 (GENETIC TUMOUR SYNDROMES OF SOFT TISSUE AND BONE)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
|- | |||
|[[STBT5:Enchondromatosis|Enchondromatosis]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
|[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |- | ||
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 2,202: | Line 2,238: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[STBT5: | |[[STBT5:Werner_syndrome|Werner syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 2,235: | Line 2,260: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|}<br /> | |}<br /> | ||